Grant: Doctoral Research Award: Canada Graduate Scholarships
McGill University
$105,000.00
Personalized prediction of Alzheimer's dementia development in at-risk individuals with mild cognitive impairment
EF 2020-21
Résumé
Since pathology from Alzheimer's disease (AD) can develop in the brain up to 20 years before symptoms appear, early diagnosis is needed to ensure treatment is started before significant brain damage develops. People with mild cognitive impairment (MCI) may present measurable cognitive decline and are at high risk for dementia. These individuals are also important candidates for pharmaceutical trials of new AD treatments. However, it is very difficult to identify which individuals with MCI will go on to develop AD dementia. Existing methods of detecting AD pathology are either too costly to be used widely (e.g., positron emission tomography), or are not accurate enough on their own to be reliable prognostic tools in the clinic (e.g., magnetic resonance imaging (MRI) or cognitive testing). In my project, I will develop the DaMoCLES score (Decline prediction using MRI, Cognition, and LifEStyle data). DaMoCLES will predict MCI conversion to AD dementia using (1) results of standard cognitive tests, (2) results of advanced MRI analyses detecting AD brain damage, (3) demographics, and (4) cardiovascular lifestyle risk factors (e.g., smoking, obesity, physical activity). I will use baseline and followup data (cognitive, clinical, and MRI) on over 900 MCI subjects in three existing studies to develop and test DaMoCLES. I will validate DaMoCLES prospectively in an independent dataset by predicting MCI conversion to AD in 400 MCI subjects from the Canada-wide COMPASS-ND study. DaMoCLES will identify key predictors for AD dementia and highlight new directions for research and intervention in early AD. Clinicians will use DaMoCLES to identify which MCI patients will develop AD dementia, aiding the design of personalized treatments to slow its progression. DaMoCLES will help optimize clinical trials for new treatments by enriching with MCI patients having AD-related cognitive decline. Optimized recruiting will shorten trial times and accelerate new treatment development.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
439469
Name
Andrews Daniel
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Personalized prediction of Alzheimer's dementia development in at-risk individuals with mild cognitive impairment
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Aging; Alzheimer'S Disease; Biomarker; Cognitive Decline; Cognitive Testing; Image Processing; Machine Learning; Magnetic Resonance Imaging; Prognosis
Abstract
Since pathology from Alzheimer's disease (AD) can develop in the brain up to 20 years before symptoms appear, early diagnosis is needed to ensure treatment is started before significant brain damage develops. People with mild cognitive impairment (MCI) may present measurable cognitive decline and are at high risk for dementia. These individuals are also important candidates for pharmaceutical trials of new AD treatments. However, it is very difficult to identify which individuals with MCI will go on to develop AD dementia. Existing methods of detecting AD pathology are either too costly to be used widely (e.g., positron emission tomography), or are not accurate enough on their own to be reliable prognostic tools in the clinic (e.g., magnetic resonance imaging (MRI) or cognitive testing). In my project, I will develop the DaMoCLES score (Decline prediction using MRI, Cognition, and LifEStyle data). DaMoCLES will predict MCI conversion to AD dementia using (1) results of standard cognitive tests, (2) results of advanced MRI analyses detecting AD brain damage, (3) demographics, and (4) cardiovascular lifestyle risk factors (e.g., smoking, obesity, physical activity). I will use baseline and followup data (cognitive, clinical, and MRI) on over 900 MCI subjects in three existing studies to develop and test DaMoCLES. I will validate DaMoCLES prospectively in an independent dataset by predicting MCI conversion to AD in 400 MCI subjects from the Canada-wide COMPASS-ND study. DaMoCLES will identify key predictors for AD dementia and highlight new directions for research and intervention in early AD. Clinicians will use DaMoCLES to identify which MCI patients will develop AD dementia, aiding the design of personalized treatments to slow its progression. DaMoCLES will help optimize clinical trials for new treatments by enriching with MCI patients having AD-related cognitive decline. Optimized recruiting will shorten trial times and accelerate new treatment development.
Competitiondate
202011
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Andrews, Daniel
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~